MedTrace Logo

Dexamethasone for Post-operative Pain After Cesarean Delivery Under Neuraxial Anesthesia.

NCT07257406 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2026-01-08

No results posted yet for this study

Summary

After surgery pain in women who have had a cesarean delivery is a determining factor in the quality and duration of their hospital stay. Insufficient pain relief can lead to longer hospitalization and long term pain, which can result in long term use of pain medication. A classic method to alleviate pain after cesarean delivery is by injecting morphine into the spinal fluid, in the women's back, in addition to prescribing morphine by mouth as needed after the surgery. However, the negative effects associated with morphine and morphine-like drugs, limit the doses used, their pain relief capacity, and can negatively affect the after surgical experience of women. An approach which uses pain relief that acts on different pain pathways to treat after surgery pain helps limit the negative effects of different drugs. The potential benefit of dexamethasone as pain relief in women who have had a cesarean delivery is all the more interesting because of its minimal negative effects compared to morphine-like drugs. Its low cost, its effectiveness to prevent nausea, and its impact on the general condition of patients make dexamethasone even more attractive.

Conditions

  • Pregnancy
  • Cesarean Delivery
  • Dexamethasone

Interventions

DRUG

Dexamethasone (IV)

Dexamethasone 8 mg IV will be given 5 minutes after cord clamping in the interventional arm.

DRUG

Placebo

This arm will receive 2 ml of saline 5 min after cord clamping.

Sponsors & Collaborators

  • Université de Montréal

    collaborator OTHER

  • Valerie Zaphiratos

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-13
Primary Completion
2021-06-08
Completion
2025-10-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07257406 on ClinicalTrials.gov